Integral Diagnostics Ltd. (AU:IDX)
ASX:IDX
IDX Stock Chart & Stats
AU$2.25
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$2.25
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$2.11 - AU$3.07
Previous CloseN/A
Volume920.11K
Average Volume (3M)911.20K
Market Cap
AU$838.92M
Enterprise ValueAU$1.65B
Total Cash (Recent Filing)AU$34.12M
Total Debt (Recent Filing)AU$841.54M
Price to Earnings (P/E)26.4
Beta0.38
Next Earnings
Aug 31, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend Yield2.65%
Share Statistics
EPS (TTM)0.02
Shares Outstanding373,066,530
10 Day Avg. Volume1,057,226
30 Day Avg. Volume911,197
Financial Highlights & Ratios
PEG Ratio-1.57
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio55.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.25Price Target Upside44.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.13
Revenue Forecast (FY)AU$801.31M
Bulls Say, Bears Say
Bulls Say
High Revenue GrowthSustained double-digit revenue expansion reflects rising scan volumes and greater clinic utilization, strengthening recurring per-scan revenue. Given the business model (per-scan fees, modality mix and contracted services), consistent top-line growth supports capacity investments and long-term market penetration.
Very High Gross Profit MarginAn exceptionally high gross margin indicates strong pricing power and low direct cost intensity for imaging and reporting services. This structural efficiency provides a durable buffer versus cost inflation and supports reinvestment in clinics, technology and radiologist capacity over the medium term.
Improved Leverage And Stable Equity BaseReduced leverage and a stable equity ratio enhance financial flexibility for acquisitions, capital expenditure and refinancing. Improved debt metrics lower solvency risk and create durable capacity to fund network expansion or technology upgrades without immediate reliance on volatile external funding.
Bears Say
Very Low Net Profit MarginExtremely slim net margins indicate that operating scale and high gross margins are not translating into shareholder earnings, likely due to elevated operating costs, amortisation or corporate overhead. Persistently low net margins constrain retained earnings and long-term return generation.
Sharp Free Cash Flow DeclineA near-60% drop in free cash flow reduces capacity to fund capex, service debt or return capital without external financing. If this trend persists it weakens liquidity resilience and may force capital allocation trade-offs that hinder durable growth initiatives and strategic investments.
Very Low Return On EquityROE near zero signals capital is generating negligible returns despite revenue growth. This structural inefficiency implies poor conversion of assets and equity into profits, risking investor returns and limiting the company's ability to attract equity capital for long-term expansion.
Integral Diagnostics Ltd. News
IDX FAQ
What was Integral Diagnostics Ltd.’s price range in the past 12 months?
Integral Diagnostics Ltd. lowest share price was AU$2.11 and its highest was AU$3.07 in the past 12 months.
What is Integral Diagnostics Ltd.’s market cap?
Integral Diagnostics Ltd.’s market cap is AU$838.92M.
When is Integral Diagnostics Ltd.’s upcoming earnings report date?
Integral Diagnostics Ltd.’s upcoming earnings report date is Aug 31, 2026 which is in 147 days.
How were Integral Diagnostics Ltd.’s earnings last quarter?
Integral Diagnostics Ltd. released its earnings results on Feb 23, 2026. The company reported AU$0.024 earnings per share for the quarter, missing the consensus estimate of AU$0.056 by -AU$0.032.
Is Integral Diagnostics Ltd. overvalued?
According to Wall Street analysts Integral Diagnostics Ltd.’s price is currently Undervalued.
Does Integral Diagnostics Ltd. pay dividends?
Integral Diagnostics Ltd. pays a Semiannually dividend of AU$0.04 which represents an annual dividend yield of 2.65%. See more information on Integral Diagnostics Ltd. dividends here
What is Integral Diagnostics Ltd.’s EPS estimate?
Integral Diagnostics Ltd.’s EPS estimate is 0.07.
How many shares outstanding does Integral Diagnostics Ltd. have?
Integral Diagnostics Ltd. has 373,066,530 shares outstanding.
What happened to Integral Diagnostics Ltd.’s price movement after its last earnings report?
Integral Diagnostics Ltd. reported an EPS of AU$0.024 in its last earnings report, missing expectations of AU$0.056. Following the earnings report the stock price went down -5.83%.
Which hedge fund is a major shareholder of Integral Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:IDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integral Diagnostics Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$3.25 (44.44% Upside)
AU$3.25 (44.44% Upside)
Blogger Sentiment
Bullish
AU:IDX Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$170.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.34%
12-Months-Change
Fundamentals
Return on Equity
2.05%
Trailing 12-Months
Asset Growth
4.81%
Trailing 12-Months
Company Description
Integral Diagnostics Ltd.
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. It provides services through 67 radiology clinics. The company was incorporated in 2008 and is headquartered in Melbourne, Australia.
IDX Stock 12 Month Forecast
Average Price Target
AU$3.25
▲(44.44% Upside)
Technical Analysis
Healius Limited
―
Genetic Signatures Ltd.
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―
Monash IVF Group Ltd
―
Options Prices
Currently, No data available
---